The article focuses on Biogen's Q4 earnings, comparing its performance to Wall Street estimates and previous year results. This is crucial for investors to assess the company's financial health and market expectations. However, without specific details on whether Biogen beat or missed estimates, the short-term impact on stock price remains neutral.